The Genetic Polymorphisms of CYP3A4*1G and CYP3A5*3 in Javanese Indonesian Population

The Genetic Polymorphisms of CYP3A4*1G and CYP3A5*3 in Javanese Indonesian


  • Sarah Atmaja Faculty of Pharmacy ,Universitas Kristen Immanuel, Yogyakarta, Indonesia
  • Ellsya Angeline Rawar Faculty of Pharmacy ,Universitas Kristen Immanuel, Yogyakarta, Indonesia
  • Ani Kristiyani Faculty of Pharmacy ,Universitas Kristen Immanuel, Yogyakarta, Indonesia
  • Dwi Aris Agung Nugrahaningsih Department of Pharmacology and Therapy Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Ahmad Hamim Sadewa Department of Biochemistry Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta , Indonesia
  • Christine Patramurti Faculty of Pharmacy, Sanata Dharma University, Yogyakarta, Indonesia



ARMS-PCR, CYP3A4*1G, CYP3A5*3, Indonesian, Javanese, Polymor-phism


Polymorphisms of CYP3A4*1G and CYP3A5*3 affect the pharmacokinetic profile of various drugs, e.g., fentanyl, tacrolimus, diltiazem, simvastatin. Tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR) is a simple and economical method for SNP determination. The polymorphisms in the CYP3A4*1G and CYP3A5*3 genes have not yet been examined using this method in Javanese Indonesian. Our aim was to determine the frequency of polymorphisms in the CYP3A4*1G and CYP3A5*3 genes in Indonesian Javanese using the ARMS-PCR method. Eighty-six patients at the Kalasan Community Health Centre in Yogyakarta, Indonesia, were chosen based on the inclusion criteria, which is Javanese ancestry. They gave their informed consent to blood collection by completing a form. Genetic variants were detected using Tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR). The chi-square test was used to determine genotype deviations from Hardy-Weinberg equilibrium, with a significant threshold of 0.05. For homozygous wild types, CYP3A4 *1/*1 dominated overall among study participants (73.35%), whereas for CYP3A5*3/*3, homozygous mutants were more prevalent (83.72%). Hardy-Weinberg equilibrium is consistent with genotype frequencies (p > 0.005). One participant carried a homozygous mutation for both CYP3A4*1G and CYP3A5*3, while the other 49 subjects were heterozygous for CYP3A4*1G and homozygous mutant for CYP3A5*3, which is the highest number of SNP combinations. The findings of the current investigation demonstrate that the population has the highest proportion of homozygous CYP3A4*1G wild-types (CYP3A4*1/*1) and homozygous mutants for CYP3A5*3 (CYP3A5*3/*3)


Zuo XC, Zhou YN, Zhang BK et al. (2013) Effect of CYP3A5*3 polymorphism on Pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metabolism and Pharmacokinetics 28 (5): 398–405. doi: 10.2133/dmpk.DMPK-12-RG-148.

Tornio A, Backman JT (2018) Cytochrome P450 in Pharmacogenetics: An Update, 1st ed. Adv Pharmacol. doi: 10.1016/bs.apha.2018.04.007

Saiz-Rodríguez M, Almenara S, Navares-Gómez M et al. (2020) Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. doi: 10.3390/biomedicines8040094

Lamba J, Hebert JM, Schietz EG et al. (2016) PharmGKB summary: Very important pharmacogene information for MT-RNR1. Pharmacogenetics and Genomics 26 (12): 558–567. doi: 10.1097/FPC.0000000000000247.

Zhang W, Chang YZ, Kan QC et al. (2010) CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. European Journal of Clinical Pharmacology 66 (1): 61–66. doi: 10.1007/s00228-009-0726-4.

Zuo XC, Ng CM, Barrett JS et al. (2013) Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: A population pharmacokinetic analysis. Pharmacogenetics and Genomics 23 (5): 251–261. doi: 10.1097/FPC.0b013e32835fcbb6.

Zhou LY, Zuo XC, Chen K et al. (2016) Significant impacts of CYP3A4∗1G and CYP3A5∗3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. Journal of Clinical Pharmacy and Therapeutics 41 (3): 341–347. doi: 10.1111/jcpt.12394.

Zhang H, Chen M, Wang X, Yu S (2017) Patients with CYP3A4∗1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection. Medicine (United States) 96 (4): 2016–2018. doi: 10.1097/MD.0000000000006013.

Zhou S, Tao M, Wang Y et al. (2019) Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects. Xenobiotica 49 (3): 375–380. doi: 10.1080/00498254.2018.1447711.

Liu X, Huang X, Zhang S et al. (2019) Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population. International Journal of Clinical Oncology 24 (2): 179–188. doi: 10.1007/s10147-018-1346-8.

Kitzmiller JP, Luzum JA, Baldassarre D et al. (2014) CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenetics and Genomics 24 (10): 486–491. doi: 10.1097/FPC.0000000000000079.

Durand P, Debray D, Kolaci M et al. (2013) Tacrolimus dose requirement in pediatric liver transplantation: Influence of CYP3A5 gene polymorphism. Pharmacogenomics 14 (9): 1017–1025. doi: 10.2217/pgs.13.87.

Honardoost MA, Tabatabaeian H, Akbari M, Salehi M (2014) Investigation of sensitivity, specificity and accuracy of Tetra primer ARMS PCR method in comparison with conventional ARMS PCR, based on sequencing technique outcomes in IVS-II-I genotyping of beta thalassemia patients. Gene 549 (1): 1–6. doi: 10.1016/j.gene.2014.05.071.

Medrano RFV, De Oliveira CA (2014) Guidelines for the tetra-primer ARMS-PCR technique development. Molecular Biotechnology 56 (7): 599–608. doi: 10.1007/s12033-014-9734-4.

Dorji PW, Tshering G, Na-Bangchang K (2019) CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: A systematic review. Journal of Clinical Pharmacy and Therapeutics 44 (4): 508–524. doi: 10.1111/jcpt.12835.

Sutrisna E, Dwiprahasto I (2011) CYP3A4* 1G gene Polymorphism on Javanese People. Indonesian Journal of Biotechnology 16 (2): 83–87. doi:

Korbie DJ, Mattick JS (2008) Touchdown PCR for increased specificity and sensitivity in PCR amplification. Nature Protocols 3 (9): 1452–1456. doi: 10.1038/nprot.2008.133.

Suhda S, Paramita DK, Fachiroh J (2016) Tetra primer ARMS PCR optimization to detect single nucleotide polymorphisms of the CYP2E1 gene. Asian Pacific Journal of Cancer Prevention 17 (7): 3065–3069. doi: 10.14456/apjcp.2016.54/APJCP.2016.17.7.3065.

Dewi AL, Paramita DK, Fachiroh J (2022) Tetra‐primer amplification refractory mutation system (ARMS) PCR used to detect 3’UTR rs1948 mutation in CHRNB4. Indonesian Journal of Biotechnology 27 (1): 1–7. doi: 10.22146/ijbiotech.64933.

Hu GX, Dai DP, Wang H et al. (2017) Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population. Pharmacogenomics 18 (4): 369–379. doi: 10.2217/pgs-2016-0179.

He BX, Shi L, Qiu J et al. (2014) The effect of CYP3A41G allele on the pharmacokinetics of atorvastatin in Chinese han patients with coronary heart disease. Journal of Clinical Pharmacology 54 (4): 462–467. doi: 10.1002/jcph.229.

Liu S, Shi X, Tian X et al. (2017) Effect of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics and pharmacodynamics of ticagrelor in healthy chinese subjects. Frontiers in Pharmacology 8 (176): 1–8. doi: 10.3389/fphar.2017.00176.

Li CJ, Li L, Lin L et al. (2014) Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PLoS ONE 9 (1): 1–9. doi: 10.1371/journal.pone.0086206.

Chan SW, Xiao Y, Hu M et al. (2016) Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. Journal of Clinical Pharmacy and Therapeutics 41 (5): 552–558. doi: 10.1111/jcpt.12433.

Priyadharsini R, Shewade DG, Subraja K et al. (2014) Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. Molecular Biology Reports 41 (11): 7265–7271. doi: 10.1007/s11033-014-3613-8.

Hong PT, Minh HHT, Thi VH, Manh3 TH (2020) Effect of CYP3A5 genotypes on serum carbamazepine concentrations at steady-state in Vietnamese epileptic patients. Res J Pharm Technol. doi: 10.5958/0974-360X.2020.00498.9

M D, Quinney KS, Clay MJ et al. (2014) Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Exp Biol Med 30 (11): 271–281. doi: 10.1055/s-0032-1323590.

Maurya MR, Gautam S, Raj JP et al. (2022) Evaluation of genetic polymorphism of CYP3A5 in normal healthy participants from western India - A cross-sectional study. Indian Journal of Pharmacology 54 (2): 97–101. doi: 10.4103/ijp.ijp_279_21.